Manufacturers report positive data for axicabtagene ciloleucel CAR T therapy for first-line treatment for high-risk large B-cell lymphoma

In an interim analysis of the ZUMA-12 phase II study, 85% of patients achieved a response following treatment with axicabtagene ciloleucel, with 74% of patients achieving a complete response.

Source:

PharmaTimes